Trials / Terminated
TerminatedNCT04652570
Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
A Phase 1b/2a Study of VB119 in Adult Subjects With Primary Membranous Nephropathy
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Tenet Medicines · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary MN
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VB119 | Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study. |
Timeline
- Start date
- 2021-05-05
- Primary completion
- 2023-11-21
- Completion
- 2024-08-15
- First posted
- 2020-12-03
- Last updated
- 2026-02-12
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04652570. Inclusion in this directory is not an endorsement.